Johns Hopkins University

Robert Siliciano

Stuart Campbell Ray

Justin R Bailey

David Lee Thomas

Yan Zhou

Joel Blankson

Ashwin Balagopal

Michel Anand Chattergoon

Katherine Bruner

Ramy El-Diwany

Haili Zhang

Three proteins, BCL-G (BCL2L14), CMPK2, and LAMP3, were discovered to independently restrict HIV-1 replication both in-vivo and in-vitro. Methods are described wherein subjects are given an effective amount of a pharmaceutical composition comprising a protein selected from the group consisting of BCL-G, CMPK2, LAMP3, functional parts thereof, recombinant proteins thereof, and combinations thereof, for the purpose of treating or preventing HIV.

Antiviral proteins and their uses in therapeutic methods

In some aspects, the invention relates to methods for determining the proportion of intact, hypermutated, deleted, and/or defective proviruses in a sample of nucleic acids, e.g., a sample obtained from a subject. The subject may be a human subject. The virus may be HIV.

Compositions and methods related to characterizing proviral reservoirs

A novel single-cell-level phenotypic assay is described, which can simultaneously analyze HIV-1 drug susceptibility and intrinsic replication capacity. This allows quantitative dissection of the functions of antiretroviral drugs into suppression of viral replication and selection of resistant viruses with diminished replication capacities. The disclosed assay provides a tool for the rational evaluation of treatment decisions for patients failing antiretroviral therapy and is expected to be an important part in clinical management of HIV.

Single cell analysis of HIV replication capacity and drug resistance

Growing community of inventors

Baltimore, MD, United States of America

Robert Siliciano